Cargando…

ANA-Negative Hydralazine-Induced Pericardial Effusion

This case describes a patient with pericardial effusion as a phenomenon of the drug-induced lupus erythematosus (DILE) syndrome due to hydralazine. The relevance of this case report lies in the fact that although hydralazine has been a known causative agent of DILE, its presentation may involve a ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeitjian, Vicken, Mehdizadeh, Azar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748098/
https://www.ncbi.nlm.nih.gov/pubmed/29391867
http://dx.doi.org/10.1155/2017/3521541
_version_ 1783289357101170688
author Zeitjian, Vicken
Mehdizadeh, Azar
author_facet Zeitjian, Vicken
Mehdizadeh, Azar
author_sort Zeitjian, Vicken
collection PubMed
description This case describes a patient with pericardial effusion as a phenomenon of the drug-induced lupus erythematosus (DILE) syndrome due to hydralazine. The relevance of this case report lies in the fact that although hydralazine has been a known causative agent of DILE, its presentation may involve a negative anti-nuclear antibody (ANA) study. Pericardial effusion is a documented adverse effect as a result of hydralazine use. It is typically common to screen for DILE with the serum ANA test prior to proceeding to more costly and specific tests (i.e., anti-histone antibody). As per our literature review, this is the second case of hydralazine causing DILE with a negative ANA. As in our case, although the screening serum ANA is the initial next best step for suspicion of DILE by hydralazine, it is important to consider the diagnosis without ANA positivity.
format Online
Article
Text
id pubmed-5748098
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-57480982018-02-01 ANA-Negative Hydralazine-Induced Pericardial Effusion Zeitjian, Vicken Mehdizadeh, Azar Case Rep Med Case Report This case describes a patient with pericardial effusion as a phenomenon of the drug-induced lupus erythematosus (DILE) syndrome due to hydralazine. The relevance of this case report lies in the fact that although hydralazine has been a known causative agent of DILE, its presentation may involve a negative anti-nuclear antibody (ANA) study. Pericardial effusion is a documented adverse effect as a result of hydralazine use. It is typically common to screen for DILE with the serum ANA test prior to proceeding to more costly and specific tests (i.e., anti-histone antibody). As per our literature review, this is the second case of hydralazine causing DILE with a negative ANA. As in our case, although the screening serum ANA is the initial next best step for suspicion of DILE by hydralazine, it is important to consider the diagnosis without ANA positivity. Hindawi 2017 2017-12-17 /pmc/articles/PMC5748098/ /pubmed/29391867 http://dx.doi.org/10.1155/2017/3521541 Text en Copyright © 2017 Vicken Zeitjian and Azar Mehdizadeh. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Zeitjian, Vicken
Mehdizadeh, Azar
ANA-Negative Hydralazine-Induced Pericardial Effusion
title ANA-Negative Hydralazine-Induced Pericardial Effusion
title_full ANA-Negative Hydralazine-Induced Pericardial Effusion
title_fullStr ANA-Negative Hydralazine-Induced Pericardial Effusion
title_full_unstemmed ANA-Negative Hydralazine-Induced Pericardial Effusion
title_short ANA-Negative Hydralazine-Induced Pericardial Effusion
title_sort ana-negative hydralazine-induced pericardial effusion
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748098/
https://www.ncbi.nlm.nih.gov/pubmed/29391867
http://dx.doi.org/10.1155/2017/3521541
work_keys_str_mv AT zeitjianvicken ananegativehydralazineinducedpericardialeffusion
AT mehdizadehazar ananegativehydralazineinducedpericardialeffusion